SELLAS Life Sciences Group, Inc. (SLS) · Nov 20, 2026 · Share issuance

SELLAS stock offering raises $150M after Phase 3 win

$150M equity raise — 11.54M shares at $13.00; $150.0M gross proceeds

SELLAS prices a $150M stock offering after its Phase 3 win, strengthening funding for FDA preparation and SLS009 while diluting existing holders.

SELLAS is a late-stage oncology biotech moving from a positive Phase 3 GPS result toward FDA preparation and potential commercialization, while continuing to develop SLS009 in AML. The raise materially strengthens that transition. SELLAS will receive $150.0 million in gross proceeds before fees from selling 11,538,462 shares at $13.00, with a further 1,730,769-share underwriter option. That gives the company fresh capital for regulatory work, launch preparation and SLS009 development rather than forcing an immediate follow-on financing after its cash balance was already $134.7 million at September 30.

The trade-off is straightforward dilution, not a change in clinical evidence. The offering was already announced, so the pricing and size are the new information; the underlying financing decision was largely known. The new shares represent roughly 5.7% of the previously outstanding share count, before any exercise of the additional-share option, while the $13 price fixes the capital cost for existing holders. 〔0〕

Bottom line: This is a modestly constructive funding event for a company entering the regulatory and commercialization phase, but it advances the story by issuing equity rather than by adding new clinical proof. The financing was partly expected, making the main change better funding visibility—not a rewritten investment case.

What to watch next

SLS009 preliminary topline data, Q4 2026

Original filing on SEC EDGAR

More SELLAS Life Sciences Group, Inc. news

SELLAS stock offering raises $150M after Phase 3 win | SLS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.